Literature DB >> 2937740

[A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].

C C Kurz, W Marget, K Harms, R M Bertele.   

Abstract

Efficacy of Oral Ofloxacin and Ciprofloxacin. Cross-over Study. The efficacy of the 4-quinolones ciprofloxacin (CPX) and ofloxacin (OFX) was studied in a cross-over study. Twenty out-patients with cystic fibrosis and chronic colonization of the respiratory tract with Pseudomonas aeruginosa were treated for ten days with OFX, then another ten days with CPX, and vice versa. Drug concentrations in serum and sputum were assayed. The patients' clinical and laboratory parameters were monitored. The side-effects that appeared did not require interrupting treatment. The serum and sputum concentrations were found to be above the minimal inhibitory concentration. Although P. aeruginosa was not eliminated by the therapy, two-thirds of the patients showed improvement during the infection that could be observed clinically and in laboratory measurements. Oral treatment with OFX and CPX is efficacious.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937740     DOI: 10.1007/bf01645207

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  2 in total

1.  [Dependence of the bactericidal activity and mutant selection of 4-quinolones on their serum concentration levels].

Authors:  A Bauernfeind; C Petermüller; B Heinrich; R Gablac
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  [Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group].

Authors:  M Verho; E E Dagrosa; V Malerczyk
Journal:  Infection       Date:  1986       Impact factor: 3.553

  2 in total
  10 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

2.  Concentration of ciprofloxacin in human serum, lung and pleural tissues and fluids during and after lung surgery.

Authors:  G Hopf; R Böcker; C J Estler; H J Radtke; W Floh
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 3.  Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.

Authors:  R Janknegt
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

4.  Ofloxacin in cystic fibrosis.

Authors:  H Meyer
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 6.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 7.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 8.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 9.  Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.

Authors:  M LeBel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 10.  Oral anti-pseudomonal antibiotics for cystic fibrosis.

Authors:  Tracey Remmington; Nikki Jahnke; Christian Harkensee
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.